5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF(V600) Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

PURPOSE: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients with previously untreated BRAF(V600) mutation–positive advanced melanoma. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo A., Dréno, Brigitte, Larkin, James, Ribas, Antoni, Liszkay, Gabriella, Maio, Michele, Mandalà, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Atkinson, Victoria, Dutriaux, Caroline, Garbe, Claus, Hsu, Jessie, Jones, Surai, Li, Haocheng, McKenna, Edward, Voulgari, Athina, McArthur, Grant A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401485/
https://www.ncbi.nlm.nih.gov/pubmed/34158360
http://dx.doi.org/10.1158/1078-0432.CCR-21-0809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401485/
https://www.ncbi.nlm.nih.gov/pubmed/34158360
http://dx.doi.org/10.1158/1078-0432.CCR-21-0809

Ejemplares similares